- JP-listed companies
- Nano Holdings, Inc.
- Financials
- Net income margin (%)
Nano Holdings, Inc. (4571)
Market cap
¥10.6B
P/E ratio
-10.2x
NANO MRNA develops RNA-based drug candidates including mRNA and siRNA therapies, then licenses them to pharmaceutical companies for late-stage development and commercialization.
| Period End | Net income margin (%) | YoY (%) |
|---|---|---|
| Mar 31, 2025 | -769.8 | +33.74% |
| Mar 31, 2024 | -575.6 | -11.22% |
| Mar 31, 2023 | -648.4 | -9.02% |
| Mar 31, 2022 | -712.7 | -21.27% |
| Mar 31, 2021 | -905.2 | +149.08% |
| Mar 31, 2020 | -363.4 | -0.18% |
| Mar 31, 2019 | -364.1 | -82.59% |
| Mar 31, 2018 | -2,090.6 | +70.85% |
| Mar 31, 2017 | -1,223.6 | +17.36% |
| Mar 31, 2016 | -1,042.6 | +3301.31% |
| Mar 31, 2015 | -30.7 | -87.00% |
| Mar 31, 2014 | -235.9 | +81.97% |
| Mar 31, 2013 | -129.6 | +12.79% |
| Mar 31, 2012 | -114.9 |